OTCMKTS:PMCB

PharmaCyte Biotech - PMCB Stock Forecast, Price & News

$2.89

-0.01 (-0.34%)

(As of 03/20/2023 12:00 AM ET)

Add

Compare

Today's Range: $2.87
▼
$2.99
50-Day Range: $2.85
▼
$3.01
52-Week Range: $1.85
▼
$3.10

Volume: 15,209 shs
Average Volume: 38,888 shs
Market Capitalization: $50.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

Headlines

SEC Filings

Short Interest

About PharmaCyte Biotech (OTCMKTS:PMCB) Stock

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

Receive PMCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter.

PMCB Stock News Headlines

February 2, 2023 | msn.com

A 45-year-old biotech CEO may have reduced his biological age by at least 5 years through a rigorous medical program that can cost up to $2 million a year, Bloomberg reported

February 2, 2023 | finance.yahoo.com

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

March 21, 2023 | Press Research (Ad)

Stocks For Smart Investors

This under-the-radar stock is in the right industry at the perfect time.

October 7, 2022 | seekingalpha.com

PharmaCyte to evaluate opportunities; CEO steps down

October 7, 2022 | markets.businessinsider.com

PharmaCyte Names Joshua Silverman Interim CEO As CEO Kenneth Waggoner Steps Down

August 15, 2022 | finance.yahoo.com

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

July 28, 2022 | finance.yahoo.com

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

July 21, 2022 | finance.yahoo.com

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

March 21, 2023 | PressReach (Ad)

This Stock Has Room To Run

Analysts believe this stock's product demand could rise quickly in the next few years.

July 11, 2022 | finance.yahoo.com

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

July 11, 2022 | finance.yahoo.com

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

July 5, 2022 | finance.yahoo.com

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

June 23, 2022 | finance.yahoo.com

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

June 15, 2022 | finance.yahoo.com

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

June 13, 2022 | finance.yahoo.com

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

June 8, 2022 | finance.yahoo.com

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

April 27, 2022 | finance.yahoo.com

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

April 19, 2022 | marketwatch.com

PharmaCyte Biotech Shares Reverse Course, Drop 8%

April 19, 2022 | finance.yahoo.com

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

April 13, 2022 | seekingalpha.com

PharmaCyte gets on with preparations for pancreatic cancer trial amid FDA clinical hold

April 13, 2022 | finance.yahoo.com

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

April 5, 2022 | finance.yahoo.com

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

March 22, 2022 | finance.yahoo.com

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

March 18, 2022 | seekingalpha.com

PharmaCyte Biotech reports Q3 results

March 16, 2022 | finance.yahoo.com

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

February 22, 2022 | finance.yahoo.com

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

February 14, 2022 | finance.yahoo.com

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PMCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter.

PMCB Company Calendar

Last Earnings: 12/15/2021
Today: 3/21/2023
Fiscal Year End: 4/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:PMCB
CUSIP: N/A
CIK: 1157075
Web: www.pharmacyte.com
Phone: (917) 595-2850
Fax: 917-595-2851
Employees: 4
Year Founded: 1996

Profitability

EPS (Most Recent Fiscal Year): ($0.26)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,240,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -6.71%
Return on Assets: -6.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 87.95
Quick Ratio: 87.95

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.34 per share
Price / Book: 0.67

Miscellaneous

Outstanding Shares: 17,440,000
Free Float: 16,461,000
Market Cap: $50.40 million
Optionable: Not Optionable
Beta: -0.02

Social Links

Key Executives

Joshua Nathaniel Silverman
Chairman, President & Chief Executive Officer

Carlos A. Trujillo
Chief Financial Officer

José L. Iglesias
Chief Medical Officer

Lilli Brandtner
Director-Diabetes Program Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PMCB Stock - Frequently Asked Questions

How have PMCB shares performed in 2023?: PharmaCyte Biotech's stock was trading at $2.93 at the beginning of the year. Since then, PMCB stock has decreased by 1.4% and is now trading at $2.89.
View the best growth stocks for 2023 here.
How were PharmaCyte Biotech's earnings last quarter?: PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) posted its earnings results on Wednesday, December, 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01.
What other stocks do shareholders of PharmaCyte Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PharmaCyte Biotech investors own include Co-Diagnostics (CODX), iBio (IBIO), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Vaxart (VXRT), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), OWC Pharmaceutical Research (OWCP), VBI Vaccines (VBIV) and Novavax (NVAX).
What is PharmaCyte Biotech's stock symbol?: PharmaCyte Biotech trades on the OTCMKTS under the ticker symbol "PMCB."

Who are PharmaCyte Biotech's major shareholders?: PharmaCyte Biotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include K2 Principal Fund L.P. (3.91%), Simplex Trading LLC (0.00%), Susquehanna International Group LLP (0.00%), Price T Rowe Associates Inc. MD (0.19%), FNY Investment Advisers LLC (0.17%) and Jane Street Group LLC (0.11%).
How do I buy shares of PharmaCyte Biotech?: Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is PharmaCyte Biotech's stock price today?: One share of PMCB stock can currently be purchased for approximately $2.89.
How much money does PharmaCyte Biotech make?: PharmaCyte Biotech (OTCMKTS:PMCB) has a market capitalization of $50.40 million. The company earns $-4,240,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.
How can I contact PharmaCyte Biotech?: PharmaCyte Biotech's mailing address is 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653. The official website for the company is www.pharmacyte.com. The company can be reached via phone at (917) 595-2850, via email at info@pharmacyte.com, or via fax at 917-595-2851.

This page (OTCMKTS:PMCB) was last updated on 3/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PharmaCyte Biotech - PMCB Stock Forecast, Price & News

About PharmaCyte Biotech (OTCMKTS:PMCB) Stock

PMCB Stock News Headlines

PMCB Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

PMCB Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info